Drug Trial Radar · NCT07487896
A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
440
Planned (sponsor's estimate)
Start
Mar 24, 2026
Primary completion
Apr 30, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a large clinical study carried out at multiple hospitals. Participants will be randomly assigned to one of two groups: one group will receive a new medicine called YL201, and the other group will receive standard chemotherapy chosen by the doctor. The purpose of the study is to see whether YL201 works better and is safer for people with locally advanced or metastatic esophageal squamous cell carcinoma whose first-line treatment has stopped working. The study will also look at how YL201 is processed in the body (Pharmacokinetics), whether it triggers any immune reactions, and whether certain biological markers can help predict how well it works.
Conditions
- Advanced Esophageal Squamous Cell Carcinoma
Interventions
YL201Drug
YL201, a B7H3 targeting ADC,administered on Day 1 of each cycle, intravenous infusion, every 3 weeks (Q3W).
PaclitaxelDrug
175 mg/m², administered on Day 1 of each cycle, intravenous infusion, every 3 weeks (Q3W).
DocetaxelDrug
75 mg/m², administered on Day 1 of each cycle, intravenous infusion, every 3 weeks (Q3W).
IrinotecanDrug
125 mg/m², administered on Days 1 and 8 of each cycle, intravenous infusion, every 3 weeks (Q3W).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to Approximately 36 Months
Locations
81 sites in 1 country. Site status is shown where the registry gives one.
144
Anqing, Anhui, China · Recruiting
135
Bengbu, Anhui, China · Recruiting
133
Hefei, Anhui, China · Recruiting
143
Hefei, Anhui, China · Recruiting
129
Beijing, Beijing Municipality, China · Recruiting
161
Beijing, Beijing Municipality, China · Recruiting
183
Beijing, Beijing Municipality, China · Recruiting
119
Chongqing, Chongqing Municipality, China · Recruiting
120
Chongqing, Chongqing Municipality, China · Recruiting
110
Fuzhou, Fujian, China · Not yet recruiting
147
Fuzhou, Fujian, China · Recruiting
145
Xiamen, Fujian, China · Recruiting
175
Lanzhou, Gansu, China · Recruiting
149
Guangzhou, Guangdong, China · Recruiting
154
Guangzhou, Guangdong, China · Recruiting
112
Nanning, Guangxi, China · Recruiting
150
Nanning, Guangxi, China · Recruiting
184
Foshan, Guangzhou, China · Recruiting
168
Meizhou, Guangzhou, China · Recruiting
169
Shantou, Guangzhou, China · Recruiting
158
Handan, Hebei, China · Recruiting
176
Handan, Hebei, China · Recruiting
180
Langfang, Hebei, China · Recruiting
156
Shijiazhuang, Hebei, China · Recruiting
159
Shijiazhuang, Hebei, China · Recruiting
122
Harbin, Heilongjiang, China · Recruiting
170
Harbin, Heilongjiang, China · Recruiting
102
Anyang, Henan, China · Recruiting
105
Luoyang, Henan, China · Recruiting
132
Nanyang, Henan, China · Recruiting
103
Zhengzhou, Henan, China · Recruiting
104
Zhengzhou, Henan, China · Recruiting
142
Zhengzhou, Henan, China · Recruiting
113
Wuhan, Hubei, China · Recruiting
114
Wuhan, Hubei, China · Recruiting
148
Wuhan, Hubei, China · Recruiting
155
Yichang, Hubei, China · Recruiting
151
Changsha, Hunan, China · Recruiting
182
Changsha, Hunan, China · Recruiting
165
Huai'an, Jiangsu, China · Recruiting
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.